CDMO

CDMO vs CMO

The distinction is the D. A CMO manufactures to a process you hand it. A CDMO will also develop that process — formulation, analytical methods, scale-up, stability — and then carry it into commercial supply. Most of the industry has converged on the CDMO model because splitting development from manufacture creates a technology-transfer boundary precisely where the knowledge is most tacit.

Why nearly everyone uses one

Building sterile fill-finish or biologics capacity is a multi-year, nine-figure commitment tied to a single asset's success. For most sponsors, particularly pre-commercial biotechs, the arithmetic never favours owning it. The trade is capital efficiency against control.

Where the relationship goes wrong

The sponsor remains legally accountable. Outsourcing manufacture does not outsource responsibility — the sponsor holds the marketing authorisation, and an inspection finding at the CDMO is the sponsor's problem. This is why the quality agreement matters more than the supply agreement.

Capacity is contended. Slots for sterile fill-finish, viral vector and now peptide capacity have been genuinely scarce; a delayed campaign can cost a launch window.

Tech transfer is the risk concentrate. Most CDMO failures trace to process knowledge that was never written down, surfacing as unexplained yield loss at the receiving site.

Comparability after a change. Moving a biologic between sites requires demonstrating the product is unchanged — an exercise that can take longer than the move itself.